Trending

NSCLC

Takeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approval

Takeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approval

Takeda has had a run of bad luck with its Wave1 pipeline of new drug candidates of late,

X

Takeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approval

https://pharmaphorum.com/news/takeda-gets-a-win-for-its-wave1-pipeline-as-exkivity-nabs-fda-approval/

Merck’s targeted lung cancer drug tepotinib wins early access in UK

Merck’s targeted lung cancer drug tepotinib wins early access in UK

The UK drugs regulator has backed Merck KGaA’s MET inhibitor for the treatment of some patients with non-small

X

Merck’s targeted lung cancer drug tepotinib wins early access in UK

https://pharmaphorum.com/news/mercks-targeted-lung-cancer-drug-tepotinib-wins-early-access-in-uk/

Amgen nabs speedy approval for first-ever KRAS drug sotorasib

Amgen nabs speedy approval for first-ever KRAS drug sotorasib

After decades of mostly unsuccessful R&D, Amgen has claimed the first ever regulatory approval for a drug that

X

Amgen nabs speedy approval for first-ever KRAS drug sotorasib

https://pharmaphorum.com/news/amgen-nabs-speedy-approval-for-first-ever-kras-drug-sotorasib/

Janssen claims FDA okay for would-be Tagrisso rival Rybrevant

Janssen claims FDA okay for would-be Tagrisso rival Rybrevant

Johnson & Johnson’s Janssen division has claimed a first approval in the US for its bispecific antibody Rybrevant

X

Janssen claims FDA okay for would-be Tagrisso rival Rybrevant

https://pharmaphorum.com/news/janssen-claims-swift-fda-okay-for-precision-cancer-drug-rybrevant/

Tagrisso trial halted early after ‘overwhelming’ efficacy

Tagrisso trial halted early after ‘overwhelming’ efficacy

A phase III trial for AstraZeneca’s lung cancer drug Tagrisso (osimertinib) will be unblinded early after strong results.

X

Tagrisso trial halted early after ‘overwhelming’ efficacy

https://pharmaphorum.com/news/tagrisso-trial-halted-early-after-overwhelming-efficacy/

Keytruda approved for combination lung cancer therapy

Keytruda approved for combination lung cancer therapy

The US Food and Drug Administration (FDA) has approved Merck & Co’s Keytruda plus chemotherapy as a first-line

X

Keytruda approved for combination lung cancer therapy

https://pharmaphorum.com/news/keytruda-approved-for-combination-lung-cancer-therapy/

AZ’s Tagrisso wins new NSCLC first-line approval in Europe

AZ’s Tagrisso wins new NSCLC first-line approval in Europe

AstraZeneca has widened the licence for its cancer drug Tagrisso (osimertinib) in Europe after regulators gave it the

X

AZ’s Tagrisso wins new NSCLC first-line approval in Europe

https://pharmaphorum.com/news/az-tagrisso-nsclc-egfr-europe/

NICE recommends Pfizer’s Xalkori in rare lung cancer

NICE recommends Pfizer’s Xalkori in rare lung cancer

NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).

X

NICE recommends Pfizer’s Xalkori in rare lung cancer

https://pharmaphorum.com/news/nice-pfizers-xalkori-rare-lung-cancer/

Roche’s Tecentriq combo extends life in advanced NSCLC

Roche’s Tecentriq combo extends life in advanced NSCLC

Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in non-small cell lung cancer (NSCLC).

X

Roche’s Tecentriq combo extends life in advanced NSCLC

https://pharmaphorum.com/news/roches-tecentriq-combo-advanced-nsclc/

1 2 3 4

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com